Nifty
:
23118.60
Sensex
:
74003.82
-279.50 (-1.19%)
-777.94 (-1.04%)
Nifty
Sensex
:
:
23118.60
74003.82
-279.50 (-1.19%)
-777.94 (-1.04%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
56/99

BSE: 532523 | NSE: BIOCON

NSE BSE
382.00
15-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  391.95
  •  392.05
  •  381
  •  390.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2543144
  •  981132626.05
  •  447.15
  •  337.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 62,091.35
  • 125.36
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 73,722.45
  • 0.13%
  • 1.83

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.68%
  • 6.15%
  • 10.26%
  • FII
  • DII
  • Others
  • 8.14%
  • 21.89%
  • 8.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.84
  • 15.64
  • 4.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.65
  • 17.49
  • 0.89

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -4.52
  • -9.87
  • -27.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 61.19
  • 61.87
  • 55.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.00
  • 2.70
  • 1.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.69
  • 15.95
  • 14.92

Earnings Forecasts:

(Updated: 12-09-2026)
Description
2026
2027
2028
2029
Adj EPS
61
1
76.66
3.83
P/E Ratio
6.26
382.00
4.98
99.74
Revenue
53.13
34.99
30.63
16989.1
EBITDA
19976.1
22816.9
24781.4
3416.01
Net Income
4418.06
5306.74
5871.8
653.52
ROA
1243.04
1861.47
2085.13
0.93
P/B Ratio
0.04
0.05
0.05
2.05
ROE
1.79
1.7
1.71
2.44
FCFF
3.66
5.28
5.57
302.1
FCFF Yield
2042.3
2655.18
2575.8
0.37
Net Debt
2.48
3.22
3.13
10798.7
BVPS
9247.55
7310.65
7854.2
185.91

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
4,336.00
3,941.90
10.00%
4,516.60
4,417.00
2.25%
4,173.00
3,821.40
9.20%
4,295.50
3,590.40
19.64%
Expenses
3,488.80
3,175.80
9.86%
3,496.30
3,338.80
4.72%
3,339.50
3,069.60
8.79%
3,460.10
2,905.00
19.11%
EBITDA
847.20
766.10
10.59%
1,020.30
1,078.20
-5.37%
833.50
751.80
10.87%
835.40
685.40
21.89%
EBIDTM
19.54%
19.43%
22.59%
24.41%
19.97%
19.67%
19.45%
19.09%
Other Income
54.50
79.70
-31.62%
52.50
36.90
42.28%
117.30
34.80
237.07%
93.00
32.50
186.15%
Interest
213.20
276.70
-22.95%
231.50
212.40
8.99%
209.90
223.40
-6.04%
272.20
225.60
20.66%
Depreciation
547.40
455.00
20.31%
513.40
436.30
17.67%
515.30
425.40
21.13%
473.00
419.90
12.65%
PBT
127.60
96.90
31.68%
247.50
486.80
-49.16%
-67.80
155.90
-
171.30
98.40
74.09%
Tax
-9.20
7.70
-
48.90
27.40
78.47%
-16.00
74.80
-
38.50
71.30
-46.00%
PAT
136.80
89.20
53.36%
198.60
459.40
-56.77%
-51.80
81.10
-
132.80
27.10
390.04%
PATM
3.15%
2.26%
4.40%
10.40%
-1.24%
2.12%
3.09%
0.75%
EPS
0.87
0.23
278.26%
0.78
2.87
-72.82%
1.08
0.21
414.29%
0.63
-0.13
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
17,321.10
16,927.00
15,261.70
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
Net Sales Growth
9.83%
10.91%
3.43%
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
 
Cost Of Goods Sold
5,753.20
5,690.70
5,197.50
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
Gross Profit
11,567.90
11,236.30
10,064.20
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
GP Margin
66.79%
66.38%
65.94%
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
Total Expenditure
13,784.70
13,585.40
12,243.00
11,559.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,469.00
3,039.90
Power & Fuel Cost
-
426.40
377.90
388.90
414.80
316.40
270.30
246.10
239.80
189.00
156.40
% Of Sales
-
2.52%
2.48%
2.64%
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
Employee Cost
-
3,508.00
3,144.40
2,664.10
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
% Of Sales
-
20.72%
20.60%
18.05%
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
Manufacturing Exp.
-
1,796.20
1,655.90
2,376.90
1,917.20
1,243.50
1,019.20
864.60
721.20
510.40
519.80
% Of Sales
-
10.61%
10.85%
16.11%
17.16%
15.19%
14.27%
13.72%
13.08%
12.38%
13.36%
General & Admin Exp.
-
1,065.90
948.10
806.00
359.60
181.50
270.50
182.10
53.00
56.80
21.70
% Of Sales
-
6.30%
6.21%
5.46%
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
Selling & Distn. Exp.
-
698.80
649.90
296.60
221.60
243.80
235.90
266.30
277.50
98.20
107.40
% Of Sales
-
4.13%
4.26%
2.01%
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
Miscellaneous Exp.
-
399.40
269.30
128.60
297.40
107.70
60.40
36.10
37.20
47.40
107.40
% Of Sales
-
2.36%
1.76%
0.87%
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
EBITDA
3,536.40
3,341.60
3,018.70
3,196.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
654.40
851.20
EBITDA Margin
20.42%
19.74%
19.78%
21.66%
18.97%
18.24%
18.23%
19.95%
20.38%
15.87%
21.88%
Other Income
317.30
456.20
1,355.80
967.50
768.10
690.30
605.20
507.50
414.30
380.90
285.40
Interest
926.80
990.30
897.40
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
Depreciation
2,049.10
1,956.70
1,687.00
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
PBT
478.60
850.80
1,790.10
1,621.00
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
Tax
62.20
79.10
457.20
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
Tax Rate
13.00%
17.66%
24.23%
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
PAT
416.40
385.60
1,013.30
1,022.50
462.70
648.40
740.50
777.10
905.30
372.40
612.10
PAT before Minority Interest
495.30
368.80
1,429.40
1,297.80
643.00
771.60
846.20
899.80
1,002.60
453.10
688.10
Minority Interest
78.90
16.80
-416.10
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
PAT Margin
2.40%
2.28%
6.64%
6.93%
4.14%
7.92%
10.37%
12.33%
16.42%
9.03%
15.73%
PAT Growth
-36.60%
-61.95%
-0.90%
120.99%
-28.64%
-12.44%
-4.71%
-14.16%
143.10%
-39.16%
 
EPS
2.56
2.37
6.22
6.27
2.84
3.98
4.54
4.77
5.56
2.29
3.76

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
34,031.80
21,644.00
19,783.70
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
Share Capital
810.50
600.30
600.30
600.30
600.30
600.00
600.00
300.00
300.00
100.00
Total Reserves
32,707.00
20,618.80
18,863.30
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
Non-Current Liabilities
12,404.30
16,493.30
15,119.80
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
Secured Loans
10,476.30
10,502.50
11,267.70
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
Unsecured Loans
270.00
1,902.90
1,664.70
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
Long Term Provisions
330.30
260.80
237.60
226.50
91.70
106.20
85.80
66.10
49.30
36.00
Current Liabilities
14,069.20
14,333.80
15,358.80
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
Trade Payables
6,772.10
6,548.70
6,272.00
3,842.00
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
Other Current Liabilities
3,059.30
3,965.70
6,481.20
1,814.90
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
Short Term Borrowings
3,566.30
3,454.70
2,149.20
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
Short Term Provisions
671.50
364.70
456.40
373.60
292.30
261.80
230.90
204.30
135.60
143.20
Total Liabilities
63,095.00
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
Net Block
36,485.90
31,963.30
30,643.60
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
Gross Block
48,079.20
40,804.30
37,930.10
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
Accumulated Depreciation
11,593.30
8,841.00
7,286.50
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
Non Current Assets
45,915.20
42,253.40
40,574.20
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
Capital Work in Progress
6,986.70
8,508.40
7,993.30
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
Non Current Investment
1,089.30
679.70
684.10
742.30
370.20
743.20
108.50
182.50
63.80
188.00
Long Term Loans & Adv.
973.80
870.80
892.50
683.20
483.80
436.40
402.00
335.80
437.20
319.70
Other Non Current Assets
379.50
231.20
360.70
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
Current Assets
17,179.80
16,286.20
15,179.20
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
Current Investments
689.80
447.30
315.60
1,326.50
1,217.70
1,213.00
857.60
829.30
611.40
1,065.00
Inventories
6,085.70
4,931.10
4,943.90
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
Sundry Debtors
5,986.80
5,487.90
6,230.60
3,573.20
2,058.20
1,517.20
1,223.70
1,291.80
1,063.90
883.20
Cash & Bank
3,193.60
4,120.20
2,258.70
2,400.10
1,747.50
2,049.20
998.60
1,057.20
1,322.80
1,044.30
Other Current Assets
1,223.90
382.70
334.40
334.10
1,060.70
954.40
809.20
678.60
428.00
419.90
Short Term Loans & Adv.
804.70
917.00
1,096.00
456.40
400.50
293.30
349.90
302.30
110.20
48.40
Net Current Assets
3,110.60
1,952.40
-179.60
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
Total Assets
63,095.00
58,539.60
55,753.40
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
1,994.00
4,061.20
2,953.90
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
PBT
447.90
1,886.60
1,525.20
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
Adjustment
2,920.90
1,711.20
2,356.20
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
Changes in Working Capital
-1,132.20
923.00
-635.20
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
Cash after chg. in Working capital
2,236.60
4,520.80
3,246.20
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-242.60
-459.60
-292.30
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,082.10
-234.10
-1,004.50
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
Net Fixed Assets
-236.40
-393.50
-323.20
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
Net Investments
-13,595.10
-2,064.10
-47.80
-3,990.70
132.70
-459.90
-859.70
105.90
-310.80
-79.30
Others
11,749.40
2,223.50
-633.50
-10,030.70
-1,547.10
-3,033.90
-1,443.60
-539.10
-195.30
-203.30
Cash from Financing Activity
-923.60
-1,854.00
-2,332.70
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
Net Cash Inflow / Outflow
-1,011.70
1,973.10
-383.30
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
Opening Cash & Equivalents
2,923.80
919.50
1,299.90
653.70
897.00
824.70
659.30
449.00
710.20
757.50
Closing Cash & Equivalent
2,111.50
2,923.80
919.50
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
206.76
176.73
162.11
146.53
68.53
62.27
54.97
50.17
42.59
39.74
ROA
0.61%
2.50%
2.41%
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
ROE
1.35%
7.03%
7.00%
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
ROCE
3.26%
7.43%
7.03%
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
Fixed Asset Turnover
0.38
0.39
0.41
0.48
0.77
0.74
0.78
0.85
0.73
0.89
Receivable days
122.96
139.43
119.85
91.14
79.19
69.67
72.86
77.96
86.05
74.35
Inventory Days
118.06
117.49
112.31
105.87
92.60
84.38
71.47
58.05
60.00
54.81
Payable days
427.20
450.17
376.86
271.55
209.62
230.92
81.60
81.98
87.98
78.68
Cash Conversion Cycle
-186.17
-193.26
-144.70
-74.54
-37.84
-76.87
62.74
54.04
58.07
50.48
Total Debt/Equity
0.44
0.84
0.81
1.01
0.60
0.58
0.40
0.40
0.44
0.48
Interest Cover
1.45
3.10
2.57
3.14
15.54
20.88
19.72
18.12
10.57
33.05

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Biocon secures supply contract for Pertuzumab in Brazil
    8th Sep 2026, 09:17 AM

    The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab

    Read More
  • Biocon’s arm secures marketing approval for pegfilgrastim biosimilar in Japan
    25th Aug 2026, 10:47 AM

    This approval further strengthens the company’s portfolio of biosimilar products in Japan

    Read More
  • Biocon reports over 4-fold jump in Q1 consolidated net profit
    6th Aug 2026, 10:50 AM

    The total consolidated income of the company has increased by 9.17% at Rs 4,390.50 crore for Q1FY27

    Read More
  • Biocon - Quarterly Results
    6th Aug 2026, 00:00 AM

    Read More
  • Biocon launches Yesafili in United States
    3rd Aug 2026, 09:42 AM

    Yesafili (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg

    Read More
  • Biocon’s arm secures Health Canada’s nod for Yesintek (ustekinumab) Autoinjector Pen
    29th Jul 2026, 14:10 PM

    This approval further strengthens the company’s portfolio of immunology products in Canada

    Read More
  • Biocon gets EMA’s nod for new drug product fill finish line for Semglee at Malaysia facility
    16th Jul 2026, 10:39 AM

    Supplies to Europe from this line are expected to begin from Q2FY27

    Read More
  • Mylan Inc. exits Biocon through Rs 3,679 crore open market deals
    15th Jul 2026, 14:30 PM

    Mylan Inc. has divested its entire 5.64% stake in Biocon

    Read More
  • Biocon’s partner secures multiple insulin contracts in Malaysia
    24th Jun 2026, 11:51 AM

    Duopharma Biotech has secured multiple insulin contracts from Ministry of Health, Malaysia, valued at over 225 million Malaysian ringgit

    Read More
  • Biocon acquires stake in Ampin C&I Power Twelve
    11th Jun 2026, 10:45 AM

    This acquisition aligns with the company’s renewable energy objectives, supporting the procurement of green energy and advancing its decarbonization goals

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.